Reply to R.L. Bowen et al, M. Froehner et al, J.L. Leow et al, and C. Brady et al
J Clin Oncol
.
2016 Aug 10;34(23):2804-5.
doi: 10.1200/JCO.2016.67.9449.
Epub 2016 Jun 13.
Authors
Kevin T Nead
1
,
Greg Gaskin
2
,
Cariad Chester
3
,
Samuel Swisher-McClure
4
,
Joel T Dudley
5
,
Nicholas J Leeper
3
,
Nigam H Shah
2
Affiliations
1
Stanford University, Stanford, CA, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA kevin.nead@uphs.upenn.edu.
2
Stanford University, Stanford, CA.
3
Stanford University School of Medicine, Stanford, CA.
4
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
5
Icahn School of Medicine at Mount Sinai, New York, NY.
PMID:
27298415
PMCID:
PMC5019764
DOI:
10.1200/JCO.2016.67.9449
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Alzheimer Disease*
Androgen Antagonists / adverse effects*
Humans
Male
Risk
Substances
Androgen Antagonists